News

Following the approval of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), Samus Therapeutics is launching a Phase 1 trial in the United States to evaluate the safety of its investigational therapy PU-AD, an epichaperome inhibitor, for the treatment of Alzheimer’s…

An online test, called MemTrax, may help screen and predict the progression of cognitive impairment in Alzheimer’s and other disorders, according to a new study using artificial intelligence. The research, “Episodic-Memory Performance in Machine Learning Modeling for Predicting Cognitive Health Status Classification,” was published in…

  To enhance care for the growing number of people with Alzheimer’s and other dementia, the U.S. Department of Health and Human Services (HHS) has awarded the University of Oklahoma Health Sciences Center a $3.75 million grant. The grant will establish a partner-reliant program designed to better educate…